Mondul AM, et al. - In black and white men in the Atherosclerosis Risk in Communities (ARIC) Study, researchers investigated the use of lipid-lowering medication if it’s related to both incident and fatal prostate cancer. Prostate cancer incidence and death were investigated among 6,518 men without cancer at visit two (1990-1992), the start of the statin era, through 2012. During follow-up, information was obtained on medication use. For total (white N=541, black N=259) and fatal (white N=56, black N=34) prostate cancer overall and by race, hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression. Findings demonstrated a lower risk of prostate cancer in association with long-term lipid-lowering medication use. As per observations, current use was possibly associated with fatal prostate cancer.